A phase II, observer blind, randomized, multi center study to evaluate the safety and immunogenicity of two 0.25 ml or 0.5 ml doses of investigational vaccine and active influenza vaccine in healthy children aged 6 to less than 60 months.

Trial Profile

A phase II, observer blind, randomized, multi center study to evaluate the safety and immunogenicity of two 0.25 ml or 0.5 ml doses of investigational vaccine and active influenza vaccine in healthy children aged 6 to less than 60 months.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors Novartis
  • Most Recent Events

    • 13 Jan 2010 Patient numbers amended from 326 to 360 as reported by ClinicalTrials.gov.
    • 23 Dec 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top